anti-CD22 antibody drug-conjugates (Medarex/BMS)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD22 antibody drug-conjugates (Medarex/BMS)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionCD226 antigen blockers

TargetsCD226 antigen

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMedarex Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMedarex Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A